Evidence map›Paper›PMID 37163449›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2023

V-Set Immunoglobulin Domain-Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity.

Chenling Tang, Shu Zhang, Aygun Teymur, Bowen Yang, Fariz Nazir, Qi Cai, Ramesh Saxena, Nancy J Olsen, Chandra Mohan, Tianfu Wu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Biomarkers for systemic lupus erythematosus: A scoping review.Immunity, inflammation and disease · 2024
    Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Chenling TangDepartment of Biomedical Engineering, University of Houston, Houston, Texas.
Shu ZhangDepartment of Biomedical Engineering, University of Houston, Houston, Texas.
Aygun TeymurDepartment of Biomedical Engineering, University of Houston, Houston, Texas.
Bowen YangDepartment of Biomedical Engineering, University of Houston, Houston, Texas.
Fariz NazirDepartment of Biomedical Engineering, University of Houston, Houston, Texas.
Qi CaiDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas.
Ramesh SaxenaDivision of Nephrology, University of Texas Southwestern Medical Center, Dallas.
Nancy J OlsenDivision of Rheumatology, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.
Chandra MohanDepartment of Biomedical Engineering, University of Houston, Houston, Texas.
Tianfu WuDepartment of Biomedical Engineering, University of Houston, Houston, Texas.ORCID 0000-0003-4406-1449
University of Houston · USThe University of Texas Southwestern Medical Center · USPenn State Milton S. Hershey Medical Center · US

Funding

A biomarker panel based smart mini-array system for the homecare of autoimmune kidney diseasesR01AG062987 · NIA · UNIVERSITY OF HOUSTON · PI WU, TIANFU · 2019 to 2023
$2.2M
NIA NIH HHS R01 AG062987
6 · The paper itself

Abstract

objectiveTo discover novel serum biomarkers that have diagnostic or predictive value in lupus nephritis (LN).

methodsUsing a quantitative protein microarray, we screened for high-abundant proteome expression in the serum of patients with LN compared to healthy controls. Top candidates from this screening were validated using a larger cohort of patients with LN compared to a disease control cohort (subjects with other chronic kidney diseases) and a healthy control cohort. Promising markers were then selected using a machine-learning model and further validated with a larger patient cohort. The corresponding autoantibodies and immune complexes containing these proteins were also examined.

resultsIn total, 13 proteins were found to be significantly elevated in LN patient serum in the screening, among which 8 proteins were validated by enzyme-linked immunosorbent assay using 81 serum samples from LN patients and control subjects. Three serum markers with LN diagnostic potential were identified using feature importance analysis and further validated using 155 serum samples from LN patients and control subjects. V-set immunoglobulin domain-containing protein 4 (VSIG4) appeared to be the most promising marker in distinguishing LN from healthy controls, with an area under the curve of 0.93. VSIG4 could also discriminate active LN from inactive LN. Furthermore, serum VSIG4 levels were positively correlated with all of the following clinical parameters: the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (Spearman's rank correlation r

conclusionVSIG4 may be a promising novel serum biomarker and therapeutic target in patients with LN.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisRenal Insufficiency, ChronicBiomarkersHumansImmunoglobulin DomainsKidneyReceptors, ComplementBiomarkersReceptors, ComplementVSIG4 protein, human

Identifiers

PMID37163449
PMCPMC10524163
OpenAlexW4376131582

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.